Finoriq research workspace
ATOSSA THERAPEUTICS, INC. (ATOS) Company Overview
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of. Review ATOS filings, fundamentals, valuation, and ownership on Finoriq.
Company Snapshot
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
- Company
- ATOSSA THERAPEUTICS, INC. (ATOS)
- Ticker
- ATOS
- Market Cap
- $21.7M
- Latest Price
- $2.52
- Industry
- Biotech & Pharma
ATOSSA THERAPEUTICS, INC. (ATOS) Current Valuation Metrics
Static valuation preview for ATOSSA THERAPEUTICS, INC. (ATOS). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| Earnings YieldLatest TTM net income divided by market cap. | -186.8% | Net Income | TTM Q1 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -165.7% | Operating Cash Flow | TTM Q1 2026 |
| Price / BookMarket cap divided by stockholders' equity. | 0.66x | Stockholders' Equity | Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.